The present invention relates to novel interferon gamma polypeptide variants
having interferon gamma (IFNG) activity, methods for their preparation, pharmaceutical
compositions comprising the polypeptide variants and their use in the treatment
of diseases, in particular for the treatment of interstitial pulmonary diseases,
such as idiopathic pulmonary fibrosis.
These novel polypeptide variants all comprise the substitution S99T as compared
to the amino acid sequence of huIFNG or fragments thereof. By performing this mutation
the naturally occurring N-glycosylation site present at position 97 is significantly
better utilized.
Preferably, the variants comprise further modifications, e.g. in order
to increase the AUC of such variants when administered subcutaneously.